Opendata, web and dolomites

NEFERTITI SIGNED

NEFERTITI: A Novel Eco-Friendly, dually Efficient and Resistance-free Treatment of vaginITIs

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NEFERTITI project word cloud

Explore the words cloud of the NEFERTITI project. It provides you a very rough idea of what is the project "NEFERTITI" about.

keep    candidiasis    biofilm    infections    quality    million    yeast    causing    bacteria    close    antibiotic    ph    fungus    socioeconomic    phyph    normally    bacterial    antifungals    life    mechanism    disrupts    vcc    limited    reduce    validation    curative    overconsumption    discharge    antimicrobials    commercialisation    substance    form    unmet    contains    market    adversely    caused    least    date    delta    sme    vaginosis    vulvovaginal    450    burden    causes    rate    instrument    treatment    business    tablet    global    trial    relapse    incidence    resistance    globally    treat    candida    clinical    gardnerella    guide    preventative    plan    free    gap    prepare    heavy    vaginal    threats    performed    lactone    treatments    healthy    bay    discomfort    natural    preclinical    bv    health    lies    gedea    efficacy    supports    gda    road    eliminate    drug    prolonged    restores    commercialization    recurrent    biggest    switches    antibiotics    misdiagnosis    removed    benign    glucono   

Project "NEFERTITI" data sheet

The following table provides information about the project.

Coordinator
GEDEA BIOTECH AB 

Organization address
address: MEDICON VILLAGE SCHEELEVAGEN 2
city: LUND
postcode: 223 81
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://gedeabiotech.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GEDEA BIOTECH AB SE (LUND) coordinator 50˙000.00

Map

 Project objective

This project will develop a business plan to guide clinical validation and commercialization of pHyph, a novel treatment targeting vaginal yeast and bacterial infections. Bacterial vaginosis (BV) and vulvovaginal candidiasis (VCC) are common vaginal infections caused by bacteria (often Gardnerella) or yeast (a fungus) called Candida. 450 million globally experience at least 4 vaginal bacteria or Candida infections each year. It causes significant discomfort, adversely affects quality of life and is associated with heavy socioeconomic burden. To date, all treatments are limited to antifungals and antibiotics that show low efficacy and high relapse rate. With prolonged usage, misdiagnosis, and overconsumption, there is a high incidence of drug resistance, which the WHO considered one of the biggest threats to global health. Gedea has developed a vaginal tablet that contains the natural substance Glucono-δ-lactone (GDA), which switches Candida towards a benign yeast form, restores vaginal pH and disrupts the Candida and bacteria biofilm without causing treatment resistance. The yeast is removed through vaginal discharge. Since this is an antibiotic-free treatment, healthy bacteria that normally keep Candida at bay are also not removed and therefore a low relapse rate is expected with the use of pHyph. The product’s key feature lies in its ability to treat both yeast and bacterial infections and its use as both a preventative and curative treatment. These features are unmet by any other product on the market. Preclinical research performed to date strongly supports pHyph’s novel mechanism to treat vaginal infections, reduce recurrent infections and eliminate the need for antibiotics/antimicrobials. The proposed project will further prepare pHyph for a clinical trial. SME Instrument funding will allow Gedea to close the gap on the road towards commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEFERTITI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEFERTITI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

HAC (2019)

ADVANCED TREATMENT OF CONTAMINATED SOIL

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More